Investigating lung adenocarcinoma through the lens of Keap1/Nrf2 pathway activation

Guest speaker Dr Sarah Best from WEHI.

Sarah will be presenting Investigating lung adenocarcinoma through the lens of Keap1/Nrf2 pathway activation.

Sarah Best’s Bio: Dr Sarah Best is a Senior Postdoctoral Fellow in the Sutherland Laboratory. After completing her PhD on breast cancer in the Visvader/Lindeman Laboratory at WEHI, Sarah went to the Brigham and Women’s Hospital/Harvard Medical School in Boston to study tumour suppressor genes in squamous non-melanoma skin cancer. In 2016, Sarah returned to WEHI to work with A/Prof Sutherland on KEAP1 biology in lung cancer.

In 2018, Sarah won the Griffith University Discovery Award (Research Australia) for her work on KEAP1-mutant lung adenocarcinoma and she has been supported by the Victorian Cancer Agency Early Career Seed Grant and an NHMRC New Investigator Project Grant. Her interest lies in the genetics of solid tumours, with a focus on the design of personalised therapeutics for patients.